Fujirebio Holdings, Inc. and Sysmex Corp. have entered into an agreement to expand their contract development and manufacturing partnership for Sysmex’s Automated Immunoassay System HISCL-Series to include the field of neurodegenerative diseases. This follows their business collaboration in the field of immunoassay signed in October 2023. While Fujirebio has been developing dedicated reagents for Sysmex’s HISCL-Series since 2020, the two companies agreed in October 2023 to expand their ...